  0086-574-87934126
News
Home / News / A Brief Introduction of Icotinib

A Brief Introduction of Icotinib

Views:48     Author:Site Editor     Publish Time: 2020-08-03      Origin:Site


1.Abstract

Icotinib (cas no. 610798-31-7) is a epidermal growth factor receptor tyrosine kinase (EGRF-TKI) inhibitor. It is used for treatment of advanced non-small cell lung cancer (NSCLC). It is the first small molecule targeted anti-cancer drug with independent intellectual property rights in China developed and produced by Zhejiang Beta Pharmaceutical Co., Ltd.

It is mainly distributed in gastrointestinal tract, bladder, stomach wall, small intestine, ovary, liver and adipose tissue. Its physicochemical properties, mechanism of action and clinical efficacy in the treatment of NSCLC are comparable with similar foreign drugs Gefitinib and Erlotinib, and its safety is even superior to the above two drugs.

Icotinib


2, Basic information

Chemical name

Icotinib

English synonym

N-(3-Ethynylphenyl)-7,8,10,11,13,14-hexahydro-[1,4,7,10]tetraoxacyclododecino[2,3-g]quinazolin-4-amine

Cas No

610798-31-7

Chemical fomula

C22H21N3O4

Molecular weight

391.43

Structure

cas 610798-31-7 

 

 

 

 

 

 

 

 

 

 

 

 



3,Launched Drug

Dose form

Strength

Active ingredient

Trade name

Marketer

 

Launch country

Pack launch date

Tablet

125mg

Icotinib hydrochloride

CONMANA

Betapharma

Shanghai

Co., Ltd

China

31 Jul

2011

Icotinib Project


4, Therapeutic Category Competitors

Active ingredient

Constraint Date in US

US Generic Forecast

Afatinib dimaleate

22 Jan 2022

Highly competitive

Dacomitinib

27 Sep 2025

Delayed

Erlotinib hydrochloride



Gefitinib


Competitive

Osimertinib mesylate

25 Jul 2032

Highly competitive


As per updated researches, Icotinib have similar even better pharmacological performance than Erlotinib and Gefitinib.


The results showed that the efficacy of Icotinib hydrochloride was no worse than that of Gefitinib. The median number of disease-free progression days was 137 days in the Icotinib group and 102 days in the Gefitinib group. Median time to disease progression, 154 days in the Icotinib group and 109 days in the Gefitinib group.


In terms of safety, the incidence of adverse reactions was 60.5% for Icotinib, 70.4% for Gefitinib, 40.0% and 49.2% for rash and 18.5% and 27.6% for diarrhea. Preliminary studies suggest that the efficacy and toxicity of Icotinib is similar to that of Gefitinib and may be superior in toxicity, but oral administration is required multiple times a day.


6, Global market information

market information 1

market information 2


Market information in China

market information in china


Sandoo Pharmaceutical is a professional pharmacuetical intermediates manufacturer, offering good quality Icotinib (cas no. 610798-31-7). If you are interested in this product, pls contact us.

REQUEST A QUOTE
We have been specialized in exporting and importing pharmaceutical intermediates and chemical products as well as API.

QUICK LINKS

CONTACT US

 Tel: 0086-574-87934126
 Cell: 0086-13600625331
 Fax: 0086-574-87994093
 Whatsapp/Wechat: 0086-13600625331
 Email: info@sandoopharm.com
 Add: 9th Floor, 1#,Smart park, No.98 Chuangyuan Rd, Ningbo, Zhejiang, China

SEARCH PRODUCT

© 2021 Sandoo Pharmaceuticals and Chemicals Co., Ltd. All rights reserved.